{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:19:05Z","timestamp":1701908345707},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Choosing an optimal treatment in older patients with indolent lymphomas is a challenge for hematooncologists. They must concomitantly treat some potentially curable entities, manage other symptomatic incurable diseases and protect their patients from life-threatening toxicities. Specific recommendations for older patients with different subtypes of marginal zone lymphomas are thus required in terms of treatment and supportive care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>All the data in the literature agree that the therapeutic approach of older patients with malignant hemopathies should include the appraisal of their life expectancy and of the prognostic factors of their tumor, the evaluation of their physiological and cognitive functions and their socioeconomic environment, and their expectancy in terms of quality of life. Major progresses have, therefore, been achieved in the management of lymphoma patients of 80 years and older.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>With an optimal \u2018geriatric assessment\u2019, most of the recommended treatments are also appropriate in older marginal zone lymphoma patients. Extranodal MALT lymphoma: eradication of the pathogen is a major part of the first-line therapy. Prognosis is excellent in early stages. In advanced stages, observation and anti-CD20 antibodies with or without cytostatic drugs are recommended. Nodal MZL: Usually confined to lymph nodes, bone marrow and peripheral blood, they should be managed as follicular lymphomas. Splenic MZL: in this unique entity involving the spleen, the bone marrow and the peripheral blood. Hepatitis infection should be eradicated before considering treatment. Only symptomatic patients require to be treated by splenectomy and\/or anti-CD20 antibodies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000554","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T23:19:08Z","timestamp":1562023148000},"page":"386-393","source":"Crossref","is-referenced-by-count":7,"title":["Marginal zone lymphomas: second most common lymphomas in older patients"],"prefix":"10.1097","volume":"31","author":[{"given":"Dominique","family":"Bron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20231206","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004\u20132014: subtype analyses from the UK's Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"R3-20231206","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.beha.2016.07.002","article-title":"Epidemiology and environmental aspects of marginal zone lymphomas","volume":"30","author":"Sriskandarajah","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"R4-20231206","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization Classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R6-20231206","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"(Suppl 6)","key":"R7-20231206","doi-asserted-by":"crossref","first-page":"vi144","DOI":"10.1093\/annonc\/mdt343","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Zucca","year":"2013","journal-title":"Ann Oncol"},{"key":"R8-20231206","article-title":"BHS guidelines for the treatment of marginal zone lymphomas: 2018 update","author":"Bron","year":"2019","journal-title":"Belg J Hematol"},{"key":"R9-20231206","doi-asserted-by":"crossref","first-page":"114422","DOI":"10.18632\/oncotarget.23001","article-title":"Tailoring treatment for MALT lymphoma patients: where do we stand now ?","volume":"8","author":"Johnson","year":"2017","journal-title":"Oncotarget"},{"key":"R10-20231206","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.beha.2016.08.025","article-title":"Marginal zone lymphoma in elderly and geriatric patients","volume":"30","author":"Goede","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"R11-20231206","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3960\/jslrt.56.43","article-title":"Retrospective analysis of treatment outcomes and geriatric assessment in elderly malignant lymphoma patients","volume":"56","author":"Naito","year":"2016","journal-title":"J Clin Exp Hematop"},{"key":"R12-20231206","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R13-20231206","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CCO.0000000000000394","article-title":"Rational therapeutic choice for older patients with lymphoma","volume":"5","author":"Bron","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"R14-20231206","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.semdp.2016.11.007","article-title":"Cutaneous marginal zone lymphomas","volume":"34","author":"Swerdlow","year":"2017","journal-title":"Semin Diagn Pathol"},{"key":"R15-20231206","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.beha.2017.01.001","article-title":"Bacteria associated with marginal zone lymphomas","volume":"30","author":"Ponzoni","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"issue":"(Suppl 1)","key":"R16-20231206","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hon.2400","article-title":"The multiple faces of marginal zone lymphomas","volume":"35","author":"Raderer","year":"2017","journal-title":"Hematol Oncol"},{"key":"R17-20231206","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/oxfordjournals.annonc.a058869","article-title":"Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma","volume":"5","author":"Rohatiner","year":"1994","journal-title":"Ann Oncol"},{"key":"R18-20231206","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"key":"R19-20231206","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"key":"R20-20231206","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jgo.2015.07.006","article-title":"Identification of clinical parameters predictive of one-year survival using two geriatric tools in clinically fit older patients with hematological malignancies: major impact of cognition","volume":"6","author":"Dubruille","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"R21-20231206","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/jrr\/rrw044","article-title":"Radiotherapy for localized gastric mucosa\u2013associated lymphoid tissue lymphoma: long-term outcomes over 10 years","volume":"58","author":"Ohkubo","year":"2017","journal-title":"J Radiat Res"},{"key":"R22-20231206","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/annonc\/mdy029","article-title":"Recommendations for the clinical management of the elderly patient with malignant lymphoma","volume":"29","author":"Specht","year":"2018","journal-title":"Ann Oncol"},{"key":"R24-20231206","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11864-015-0344-6","article-title":"The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas","volume":"16","author":"Foster","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"R25-20231206","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.beha.2017.11.001","article-title":"Overview on the management of nongastric MALT lymphomas","volume":"31","author":"Defrancesco","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"R26-20231206","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.beha.2016.11.002","article-title":"Ocular adnexal marginal zone lymphoma: clinical presentation, pathogenesis, diagnosis, prognosis and treatment","volume":"30","author":"Sassone","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"R27-20231206","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with Rituximab plus Chlorambucil versus either Chlorambucil or Rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"key":"R28-20231206","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.beha.2016.11.001","article-title":"Pathology of nodal marginal zone lymphomas","volume":"30","author":"Pileri","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"R29-20231206","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.beha.2016.09.004","article-title":"Molecular pathogenesis of splenic and nodal marginal zone lymphoma","volume":"30","author":"Spina","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"R30-20231206","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.beha.2016.08.026","article-title":"Nodal marginal zone lymphoma: clinical features, diagnosis, management and treatement","volume":"30","author":"Tadmor","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"R31-20231206","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"R32-20231206","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/hon.2334","article-title":"The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma","volume":"35","author":"Laribi","year":"2016","journal-title":"Hematol Oncol"},{"key":"R33-20231206","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2018.36.15_suppl.7515","article-title":"Two years rituximab maintenance vs observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial)","volume":"36","author":"Rummel","year":"2018","journal-title":"J Clin Oncol"},{"key":"R34-20231206","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"R35-20231206","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"key":"R36-20231206","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.beha.2016.07.003","article-title":"Possible novel agents in marginal zone lymphomas","volume":"30","author":"Zinzani","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"R37-20231206","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bjh.15454","article-title":"High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study but the EBMT lymphoma working group party and FIL-GITMO","volume":"182","author":"Avivi","year":"2018","journal-title":"Br J Haematol"},{"key":"R38-20231206","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"R39-20231206","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bjhh.2016.09.014","article-title":"Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges","volume":"39","author":"Dos Santos","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"key":"R40-20231206","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/asheducation-2017.1.371","article-title":"Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma","volume":"2017","author":"Thieblemont","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R41-20231206","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3109\/10428194.2015.1092529","article-title":"Peri-operative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma","volume":"57","author":"Pata","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"R42-20231206","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.3748\/wjg.v19.i24.3854","article-title":"Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma","volume":"19","author":"Wu","year":"2013","journal-title":"Word J Gastroenterol"},{"key":"R43-20231206","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/ases.12097","article-title":"Single-incision laparoscopy: a review of the indications, techniques and results after more than 700 procedures","volume":"7","author":"Dapri","year":"2014","journal-title":"Asian J Endosc Surg"},{"key":"R44-20231206","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.beha.2017.10.011","article-title":"Should Rituximab replace splenectomy in the management of splenic marginal zone lymphoma?","volume":"31","author":"Kalpadakis","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"R45-20231206","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of Bendamustine and Rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br J Haematol"},{"key":"R46-20231206","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00270-012-0484-z","article-title":"Radioembolization of the spleen: a revisited approach for the treatment of malignant lymphomatous splenectomy","volume":"36","author":"Muylle","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R47-20231206","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5045\/br.2018.53.1.74","article-title":"A rare case of splenic diffuse red pulp small B cell lymphoma (SDRPL): a review of the litt\u00e9rature on primary splenic lymphoma with hairy cells","volume":"53","author":"Vig","year":"2018","journal-title":"Blood Res"},{"key":"R48-20231206","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bjh.14524","article-title":"How I manage patients with hairy cell leukaemia","volume":"177","author":"Thompson","year":"2017","journal-title":"Br J Haematol"},{"key":"R49-20231206","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2018.11.002","article-title":"Novel therapeutics in the treatment of hairy cell leukemia variant","volume":"75","author":"Letendre","year":"2018","journal-title":"Leuk Res"},{"key":"R50-20231206","doi-asserted-by":"crossref","first-page":"110727","DOI":"10.18632\/oncotarget.21304","article-title":"Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases","volume":"8","author":"Visentin","year":"2017","journal-title":"Oncotarget"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T10:02:19Z","timestamp":1701856939000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000554","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}